| Bioactivity | LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells[1]. |
| CAS | 2549160-15-6 |
| Formula | C23H20F3N3O3 |
| Molar Mass | 443.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Andrade AAR, et al., Antiproliferative Activity of N-Acylhydrazone Derivative on Hepatocellular Carcinoma Cells Involves Transcriptional Regulation of Genes Required for G2/M Transition. Biomedicines. 2024 Apr 18;12(4):892. |
LASSBio-2052
CAS: 2549160-15-6 F: C23H20F3N3O3 W: 443.42
LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.